9-[2-(3-bromophenyl)-2-oxoethyl]-8-phenyl-2-pyridin-4-yl-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 9-[2-(3-bromophenyl)-2-oxoethyl]-8-phenyl-2-pyridin-4-yl-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one
• 化学式: C₂₆H₂₁BrN₄O₂
• 分子量: 501.4
• InChiKey: ZWIGYTCEFZPKKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1460075A1

  公开（公告）日：2004-09-22

  The invention relates to substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, a carbonyl group, a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the rings being optionally substituted; R2 represents a phenyl group or a naphthalene ring; the phenyl group and the naphthalene ring being optionally substituted; R3 represents a hydrogen atom or a C1-6 alkyl group; R4 represents a phenyl group, a pyridinyl group or a naphthalene ring, the groups and the ring being optionally substituted; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; n represents 0 to 3; and p+q=0-3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  该发明涉及由式(I)表示的取代嘧啶酮衍生物或其盐：其中：X代表两个氢原子、一个硫原子、一个氧原子或一个C1-2烷基基团和一个氢原子；Y代表一个键、一个羰基、一个可选择取代的亚甲基基团；R1代表一个2、3或4-吡啶环或一个2、4或5-嘧啶环，环可选择取代；R2代表一个苯基或一个萘环；苯基和萘环可选择取代；R3代表一个氢原子或一个C1-6烷基基团；R4代表一个苯基、一个吡啶基团或一个萘环，基团和环可选择取代；R5代表一个氢原子、一个C1-6烷基基团或一个卤原子；n表示0到3；p+q=0-3。该发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives
  申请人：Lochead Alistair

  公开号：US20060035885A1

  公开（公告）日：2006-02-16

  The invention relates to substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer's disease.

  本发明涉及由式（I）或其盐所代表的取代嘧啶酮衍生物：其中X、Y、R1、R2、R3、R4、R5、n、p和q如本文所定义。本发明还涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
  申请人：LOCHEAD Alistair

  公开号：US20080021046A1

  公开（公告）日：2008-01-24

  The invention relates to use of substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of GSK3β, such as Pick's disease among various other diseases as claimed herein.

  本发明涉及使用式（I）或其盐所代表的取代嘧啶酮衍生物，其中X，Y，R1，R2，R3，R4，R5，n，p和q如本文所定义。更具体地，本发明涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的疾病，例如Pick氏病以及其他各种疾病。
• 8-SUBSTITUTED-6, 7, 8,9-TETRAHY9DROPYRIMIDO (1,2- a) PYRIMIDIN-4-ONE DERIVATIVES
  申请人：Sanofi-Aventis

  公开号：EP1608654B1

  公开（公告）日：2009-12-23
• US7247638B2
  申请人：——

  公开号：US7247638B2

  公开（公告）日：2007-07-24